

## Special Issue

# Vaginal Cancer: From Pathology to Treatment

### Message from the Guest Editor

Primary vaginal carcinoma is one of the rarest neoplasms. Worldwide, about 18,000 new cases are documented each year, which corresponds to one per thousand out of all cancers and 1% of all gynaecological cancers. Expressed differently, just as many women develop vaginal carcinoma as men develop breast cancer. However, about 8000 deaths per year worldwide are attributed to vaginal cancer. This indicates that both morbidity and mortality are not negligible. Like most rare diseases, though, the situation with regard to randomised trials or larger collectives is very poor. In this Special Issue, you will find recent research on pathological, translational and clinical aspects of vaginal neoplasms. We look forward to receiving original research papers and reviews on these relevant, rare topics for all vaginal precancerous lesions and malignancies, their prognosis and possible treatment options.

---

### Guest Editor

Dr. Dirk Michael Forner  
Evangelisches Krankenhaus Kalk gGmbH, Köln, Germany

---

### Deadline for manuscript submissions

closed (15 August 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/168623](https://mdpi.com/si/168623)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)